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Introduction
The standard of care for patients with hemophilia A is replace-
ment therapy with intravenous infusion of either plasma-derived 
or recombinant factor VIII (rFVIII) concentrates [1]. Although 
several of these products are currently available [2] and included in 
treatment guidelines [1], improvements in product efficacy, safety, 
and convenience of administration continue to be a focus of rational 
bioengineering.
One of the principal areas of potential improvement in FVIII 
products is their pharmacokinetic (PK) profile. For example, 
coagulation factors are large proteins and tend to have a relatively 
short half-life; this means that frequent dosing is needed to 
maintain therapeutic concentrations [3]. Prophylactic treatment 
with currently available FVIII products necessitates intravenous 
injections up to three times a week [1]. Increasing the half-life of 
a FVIII product may permit a less frequent dosing regimen, making 
therapy more convenient for patients and clinicians alike, and 
potentially improving compliance [3]. It also has the potential to 
increase the uptake of prophylactic therapy, with the associated 
benefit of improved joint health [4]. Although prolonging the half-
life of a product is a clear research aim, there are various constraints 
on the methodologies that can be used to do this. For example, 
the biological activity of the protein needs to be maintained 
if any structural changes are made that affect its half-life, and 
any modifications that are made must not increase the risk of 
immunogenicity [3].
Preclinical profile of rVIII-SingleChain
Recent advances in coagulation factor therapy include the 
development of a unique recombinant single-chain FVIII protein, 
rVIII-SingleChain. This protein is expressed in Chinese hamster ovary 
(CHO) cells and purified using chromatographic techniques [5]. It 
has been designed as a B-domain-truncated rFVIII molecule where 
the light and heavy chains are covalently linked, thereby forming 
a stable single-chain rFVIII [5]. This novel design is in contrast to 
other commercially available rFVIII preparations, which comprise 
two-chain molecules [5]. In addition, whereas the heavy and light 
chains in the native and other recombinant proteins are linked via 
a labile metal–ion bridge [6,7], the heavy and light chain segments 
in rVIII-SingleChain are linked by a stronger covalent bond, making 
them less likely to dissociate [5]. This is supported by an analysis 
of rVIII-SingleChain using size-exclusion high-performance liquid 
chromatography, which revealed one sharp elution peak, indicating 
that rVIII-SingleChain can be isolated as a homogeneous and pure 
compound. In contrast, full-length rFVIII produced a pattern that 
included multiple smaller peaks, likely owing to the heterogeneity 
of the residual B-domain [5]. Together, these novel features of 
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For patients with hemophilia A, replacement of deficient factor VIII (FVIII) using plasma-derived or 
recombinant FVIII (rFVIII) products to restore hemostatic control can reduce bleeding complications and 
preserve musculoskeletal function. Despite the clinical availability of several of these products, challenges 
remain in the treatment of hemophilia A, the most notable of which are the risk of inhibitor development 
and the limited half-life of existing FVIII concentrates, which can make prophylaxis burdensome for patients. 
The use of recombinant protein technology may lead to novel FVIII products with improved properties. This 
article describes the story of a unique recombinant FVIII protein, rVIII-SingleChain, which is currently in 
development. In contrast to native FVIII and other commercially available rFVIII preparations, rVIII-SingleChain 
uses a strong, covalent bond to connect the light and heavy chains, thereby creating a stable, single-chain 
rFVIII. It has enhanced intrinsic stability, better integrity after reconstitution, and a higher binding affinity to 
von Willebrand factor. The physicochemical profile of rVIII-SingleChain and preclinical data on its activity and 
phamacokinetics strengthened the rationale for its clinical investigation. Available data from the AFFINITY 
clinical trial program are promising; indicating that it has good hemostatic efficacy when used on demand, 
for prophylaxis, and in the surgical setting, and is also very well tolerated. A pediatric study and an extension 
study are ongoing as part of the AFFINITY program.
© 2016 Elsevier Ltd. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
Review
The story of a unique molecule in hemophilia A: recombinant single-chain factor VIII
Ingrid Pabinger-Fasching*
Clinical Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
* Corresponding author at: Universitätsklinik für Innere Medizin I, Klinische 
Abteilung für Hämatologie und Hämostaseologie, Währinger Gürtel 18–20 A-1090, 
Wien, Austria. Tel.: +43 1 40400 4952; fax: +43 1 40402 6930.
 E-mail address: Ingrid.pabinger@meduniwien.ac.at (I. Pabinger-Fasching).
0049-3848/© 2016 Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
 I. Pabinger-Fasching / Thrombosis Research 141S3 (2016) S2–S4 S3
rVIII-SingleChain are likely to improve its intrinsic stability and 
make it easier to maintain its anticoagulant properties when it is in 
solution during manufacture and storage [5].
The inactive form of FVIII circulates in a non-covalent complex 
with von Willebrand factor (VWF), which stabilizes FVIII, prevents 
its premature activation and clearance, and may play a role in 
localizing FVIII to sites of vascular injury [8]. FVIII is then activated 
by thrombin or factor Xa by means of proteolytic cleavage of the light 
and heavy chains, and is released from VWF as activated FVIII [8]. 
Interestingly, rVIII-SingleChain has a higher affinity for VWF than 
other FVIII molecules [9]. The difference between the two products 
in the equilibrium dissociation constant is largely driven by the fact 
that rVIII-SingleChain has a higher association rate constant than 
full-length rFVIII [9]. From these findings, we can conclude that the 
binding of rVIII-SingleChain to VWF is both faster and stronger than 
that of full-length rFVIII [9]. Similar findings have been shown in 
mouse models of hemophilia A [9]. As the role of VWF is to bind 
FVIII and prevent premature proteolysis and clearance, tighter 
binding of rVIII-SingleChain to VWF may reduce its clearance rate 
and extend its half-life until it more closely matches that of VWF. 
Studies in animal models support this, showing that the half-life of 
rVIII-SingleChain was approximately twice that of full-length rFVIII 
[9].
It is essential that rVIII-SingleChain can fulfill the same function 
within the coagulation pathway as the native protein. With this in 
mind, rVIII-SingleChain has been designed so that key thrombin 
cleavage sites required for its activation are unchanged; the active 
form should therefore be structurally comparable to that produced 
by other commercially available preparations [5]. Preclinical 
data support this, showing a high degree of tyrosine sulfation in 
rVIII-SingleChain, including in those positions that are important 
for binding to VWF or thrombin [5]. Analysis of thrombin digests 
of rVIII-SingleChain, full-length rFVIII, and B-domain-deleted rFVIII 
using reverse-phase high-performance liquid chromatography 
showed that the main peaks of all products eluted at the same 
retention time, indicating similarity [5]. Further support is provided 
by experiments using FVIII-deficient mouse models to assess the 
activation of rVIII-SingleChain by thrombin, which indicate that 
rVIII-SingleChain has similar biological activity to that of full-length 
rFVIII [5]. It also has similar efficacy in reducing blood loss during 
tail-tip bleeding in mouse models [10]. Lastly, analysis of post-
translational N-glycosylation of rVIII-SingleChain using high-pH 
anion exchange chromatography showed a pattern that is similar 
to that seen in other FVIII proteins that are expressed in CHO cells 
[11]. In summary, the physicochemical profile of rVIII-SingleChain is 
similar to that of commercially available rFVIII products in terms of 
post-translational modification and biological activity [5,11].
Moving on to the clinic, PK profiling has been undertaken to 
determine whether rVIII-SingleChain exhibits the PK properties that 
would be expected given its molecular structure and preclinical data. 
Subsequent evaluation of the effect of rVIII-SingleChain on clinical 
outcomes will provide insights into whether this novel protein can 
improve patient management in hemophilia A. Both the PK profiling 
and the clinical evaluation are part of the AFFINITY clinical trial 
program, which is now well underway and is already providing 
insights into the use of rVIII-SingleChain in the clinical setting.
The AFFINITY clinical trial program: design
The AFFINITY clinical trial program was designed as a large 
interconnected series of Phase I/III studies to evaluate the efficacy, 
safety, and PK of rVIII-SingleChain. Participants include previously 
treated adults, adolescents, or children aged 12–65 years with severe 
hemophilia A [10]. The first phase of the program is divided into 
three parts, followed by a Phase III pediatric trial and an extension 
trial.
AFFINITY study in adults and adolescents
Part 1 of the study characterized the PK profile and short-term safety 
of a single dose of rVIII-SingleChain compared with a recombinant 
full-length rFVIII (octocog alfa; Advate®). Approximately 30 pre viously 
treated patients aged ≥18 years received one intravenous infusion 
of octocog alfa at 50 IU/kg and PK was measured over 72 hours. 
After a 4-day washout period, PK analysis was repeated after an 
intravenous infusion of rVIII-SingleChain [12]. Blood samples for PK 
analysis were collected pre-dose and up to 72 hours after dosing.
Patients who completed Part 1 of the study could then enter 
Part 2, in which they received multiple doses of rVIII-SingleChain as 
on-demand or prophylactic treatment. The results of Parts 1 and 2 
informed the treatment dose and schedule for Part 3 of the study.
In Part 3, additional patients, including adolescents (12 to <18 years) 
and adults (18–65 years) who were receiving rVIII-SingleChain as 
on-demand or prophylactic treatment were included to provide a 
larger dataset for efficacy and safety analyses, with a subset of these 
patients also undergoing a single-dose PK assessment, as required 
by the European Medicines Agency [10]. A subgroup analysis of 13 
participants who underwent elective surgery was included in the 
study design so that data could be collected on rVIII-SingleChain 
efficacy in the challenging perioperative setting [13]. After 
completion of Parts 1–3 of the study, eligible patients could enter 
the extension study in which they continue to receive treatment 
with rVIII-SingleChain [10]; this will provide long-term safety data. 
Parts 1–3 of the AFFINITY study have now been completed, and the 
extension study is ongoing [14].
AFFINITY study in children
In addition to the study described above, a Phase III, open-label 
study is ongoing in pediatric patients with severe hemophilia A [15]. 
Two groups are included in the study: one of previously treated 
patients who are 6 to <12 years old, and one of patients aged 0 to 
<6 years who have had over 50 exposure days with a previous FVIII 
product. Each group will include at least 25 patients, and will receive 
either on-demand or prophylactic treatment with rVIII-SingleChain 
at a dose decided by the investigator. The primary outcome measure 
in the study is rate of treatment success, defined as an investigator 
rating of ‘excellent’ or ‘good’ for hemostatic efficacy on a four-point 
scale of excellent, good, moderate, or poor/no response. Secondary 
outcome measures include annualized bleeding rate, proportion 
of bleeding episodes requiring multiple infusions to achieve 
hemostasis, rVIII-SingleChain consumption, and PK parameters of 
rVIII-SingleChain [15]. Study enrollment is now complete and data 
for the primary outcome measure are expected soon.
Further clinical studies are planned, including a study in pre-
viously untreated patients to assess the rate of inhibitor development 
with rVIII-SingleChain; it is hoped that this study will be particularly 
interesting, given the unique structure of rVIII-SingleChain and its 
enhanced binding to VWF [10].
The AFFINITY clinical trial program: preliminary results
PK profile of rVIII-SingleChain
A preliminary PK analysis has been carried out combining 
available data on rVIII-SingleChain from the two AFFINITY studies 
described above, i.e. data from adults (≥18 years old), adolescents (12 
to <18 years old), and pediatrics (0 to <12 years old) [16]. In adults 
and adolescents, PK samples were collected pre-dose and up to 
96 hours post-dose; in pediatrics, sampling was performed pre-dose 
and up to 48 hours post-dose. Early findings demonstrate favorable 
PK. As expected, mean half-life was shorter and mean clearance was 
greater in pediatrics compared with adults and adolescents.
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Efficacy and safety of rVIII-SingleChain in adults and adolescents
Overall, 175 patients were enrolled in Parts 2 and 3 of the study, 
of whom 173 received treatment with rVIII-SingleChain (27 as on-
demand and 146 as prophylactic therapy) [17]. The total number of 
exposure days in the study was 14,293; 120 patients were treated 
for more than 50 exposure days. During that time, 830 bleeds were 
treated, and the hemostatic efficacy of rVIII-SingleChain was rated 
as excellent or good in 94% of cases. With regard to dosing, 6% of 
patients who received prophylaxis were dosed every other day, 54% 
were dosed three times per week, 32% were dosed twice per week, 
and 8% followed other dosing regimens. The median annualized 
bleeding rate in those receiving prophylaxis was low. No inhibitor 
development was observed during the course of the study. In 
summary, these data indicate that rVIII-SingleChain is efficacious 
when used on-demand or as prophylaxis, and has a good safety 
profile.
Efficacy and safety of rVIII-SingleChain in surgical prophylaxis
The subgroup analysis that investigated the safety and efficacy of 
rVIII-SingleChain in the perioperative setting included 13 patients 
who underwent 16 major surgeries: wisdom teeth extraction, 
abdominal hernia repair, elbow replacement, ankle arthroplasty, five 
knee replacements, cholecystectomy, lengthening of the Achilles 
tendon combined with toe straightening, three circumcisions, 
surgery on an ankle fracture, and ankle hardware removal [13]. 
Administration of rVIII-SingleChain was via bolus infusion in eight 
cases and via continuous infusion in the remaining eight cases; 
dosing was according to the World Federation of Hemophilia 
guidelines and tailored to the individual patient’s PK profile. On 
a four-point scale from excellent to poor/no response, hemostatic 
efficacy of rVIII-SingleChain during surgery was rated as excellent 
in all cases except for one, in which it was rated good. No related 
adverse events or serious adverse events were observed during the 
peri-surgical period [13].
Conclusions
The development of rVIII-SingleChain has included a compre-
hensive preclinical evaluation during which several unique features 
were highlighted and which may translate into improved clinical 
care for patients with hemophilia A. These include an improved 
PK profile, with the potential for less frequent dosing. Available 
data from the AFFINITY clinical trial program are promising so far, 
demonstrating that rVIII-SingleChain has a lower clearance, a greater 
area under the curve, and a longer half-life compared with full-
length rFVIII. Clinical studies indicate that it has good hemostatic 
efficacy when used on-demand, for prophylaxis, and for surgical 
procedures. Furthermore, rVIII-SingleChain appears to be very well 
tolerated. The AFFINITY pediatric and extension studies are ongoing 
and further data are eagerly awaited.
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